Henrik Wernérus
Nessuna posizione attualmente
Storia della carriera di Henrik Wernérus
Precedenti posizioni note di Henrik Wernérus
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Atlas Antibodies AB
 Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | - |
| Fondatore | 01/01/2006 | - |
Formazione di Henrik Wernérus
| Royal Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Svezia | 3 |
Posizioni
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Atlas Antibodies AB
Atlas Antibodies AB BiotechnologyHealth Technology Atlas Antibodies AB develops antibodies and reagents for Mass Spectrometry (MS)-based quantitative proteomics. Its project Human Protein Atlas aim to present an expression map of the complete human proteome. It offers characterized antibodies to various protein coding human genes; Triple A Polyclonals that are research grade rabbit polyclonal antibodies; and mouse monoclonal antibodies to selected proteins, as a complement to rabbit polyclonal antibodies. Its antibodies are used to study human proteins, for basic research purposes and clinical research in various disease areas, such as cancer and neurological brain diseases. The company was founded by Jan Fredrik Pontén, Karin Marianne Hansson, Henrik Wernérus, and Carl Erik Mathias Uhlén in 2006 and is headquartered in Stockholm, Sweden. | Health Technology |
- Borsa valori
- Insiders
- Henrik Wernérus
- Esperienza
